Short-, long-course therapy comparable in T3 rectal cancer

Short-, long-course therapy comparable in T3 rectal cancer
There are no statistically significant differences in the rates of local recurrence, distant recurrence, relapse-free survival, overall survival, or late toxicity in patients treated with short-course radiotherapy or long-course chemoradiation, according to research published online Sept. 24 in the Journal of Clinical Oncology.

(HealthDay)—There are no statistically significant differences in the rates of local recurrence (LR), distant recurrence, relapse-free survival, overall survival, or late toxicity in patients treated with short-course (SC) radiotherapy or long-course (LC) chemoradiation, according to research published online Sept. 24 in the Journal of Clinical Oncology.

Samuel Y. Ngan, M.D., of the Peter MacCallum Cancer Centre in Melbourne, Australia, and colleagues conducted a study involving 326 patients with T3N0-2M0 rectal adenocarcinoma to compare the LR rate between SC and LC neoadjuvant radiotherapy for rectal cancer. SC consisted of pelvic radiotherapy, early surgery, and six courses of adjuvant chemotherapy, while LC included with continuous infusional fluorouracil, followed by surgery and four chemotherapy courses.

The researchers found the three-year LR rates to be 7.5 and 4.4 percent for SC and LC, respectively. Five-year distant recurrence rates were 27 and 30 percent for SC and LC, respectively. Overall five-year were 74 versus 70 percent. Finally, late toxicity rates were not substantially different for SC- and LC-treated patients. None of these differences were statistically significant.

"The trial data indicate that LC may be more effective than SC in reducing the risk of LR, especially for distal tumors," the authors write. "However, we have not been able to definitively determine that such a difference does exist, and further study would be required to help clarify this issue."

One author disclosed to pharmaceutical companies.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Docetaxel given after doxorubicin reduces recurrence

date Jan 08, 2008

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the Na ...

Early response is an indicator for rectal cancer survival

date Apr 10, 2012

(HealthDay) -- In patients with locally advanced rectal cancer undergoing radical resection, response to neoadjuvant chemoradiotherapy is an early marker that correlates with rates of recurrence-free survival, ...

When liquid crystals with a metal center are 'shaking hands'

date Mar 14, 2005

Without liquid crystals (LC's) our cell phones and notebook computers would not be possible, for these compounds keep our display screens flat and lightweight. Being a phase of matter whose order is intermediate between that ...

Recommended for you

DNA blood test detects lung cancer mutations

date 11 hours ago

Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimise treatment when tumour tissue is not available, an international group of researchers ...

Tumors prefer the easy way out

date 13 hours ago

Tumor cells become lethal when they spread. Blocking this process can be a powerful way to stop cancer. Historically, scientists thought that tumor cells migrated by brute force, actively pushing through whatever ...

Brain tumors may be new targets of Ebola-like virus

date 13 hours ago

Brain tumors are notoriously difficult for most drugs to reach, but Yale researchers have found a promising but unlikely new ally against brain cancers—portions of a deadly virus similar to Ebola.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.